World-leading business angel syndicate investing in early-stage Scottish life sciences and technology companies.
The Stirling-based materials company will expand its production footprint and workforce after closing its latest investment.
"This investment marks a real tipping point for Integrated Graphene and the manufacturing of our unique 3D Graphene foam in its first two market-ready products. By investing now, we will be ready, this year, to produce millions of units per annum from a new facility in Stirling and to transfer the technology at scale to global partners in the future."
The funding round was led by Archangels to support international expansion and product development.
"In a post-pandemic world, web-based clinical triage is becoming an increasingly an important part of how healthcare is delivered in the UK and globally, providing a vital service and reducing the burden on healthcare teams. I have no doubt that the clinical depth of the PhysioWizard product, which has been developed over many years, will ensure that it becomes the leading digital triage solution not only in the UK but globally."
Archangels led the financing round to support the development of the company cell analysis platform.
"On behalf of our Board and employees I would like to thank our investors for their continued support of Cytomos. We now have the growth capital required to advance the development of our novel process analytical technology platform to the next phase of prototype evaluation with our strategic partners. This is an important milestone in the journey to deliver our mission to enable the development and manufacture of life saving biologic therapies"
Archangels has backed Earth Blox in a £1.5m seed round to support product development and market expansion.
"We are very pleased to secure this funding from Archangels and join a strong portfolio of businesses in the life sciences and tech sectors. Investment into innovative businesses like ours is vital to growth in all areas, from customer acquisition to building a great team. This investment will help us develop Earth Blox as a scalable SaaS and get the power of Earth observation insights into the hands of a range of users around the world."
The funding round was led by Archangels to support human trials of the BioCaptis device.
"BIOCAPTIVA is at the forefront of developing technology to transform liquid biopsy testing in cancer management. We are pleased to have raised these additional funds as the company enters its next stage of development, with the BioCaptis beginning its first in human trials. These trials will allow us to generate important data before the end of 2022. This will be a key step before starting regulatory trials in 2023 as we move towards our goal of unleashing the full potential of liquid biopsy in cancer management to improve patient outcomes."
